Baker Bros. Advisors’s LB Pharmaceuticals LBRX Stock Holding History

Baker Bros. Advisors’s Portfolio LBRX Stock Details LBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.49M	Hold	200,000	–	–	0.03%	74
2026 Q1	$4.93M	Hold	200,000	–	–	0.03%	77
2025 Q4	$4.45M	Hold	200,000	–	–	0.03%	75
2025 Q3	$3.16M	Buy	+200,000	New	+$3.17M	0.02%	77

Other funds holding LBRX

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Baker Bros. Advisors's LBRX Position: Q2 2026 in Review

Baker Bros. Advisors held its LB Pharmaceuticals (LBRX) position steady in Q2 2026 at 200,000 shares worth $6.49M. The position accounts for 0.03% of the portfolio, ranked #74.

Baker Bros. Advisors first reported a position in LBRX in Q3 2025 and has held it in 4 quarters since. 115 funds tracked by Wall St. Rank hold LBRX as of Q2 2026.

Baker Bros. Advisors held 200,000 shares of LB Pharmaceuticals worth $6.49M as of Q2 2026.
Baker Bros. Advisors left its LB Pharmaceuticals share count unchanged in Q2 2026.
LB Pharmaceuticals made up 0.03% of Baker Bros. Advisors's portfolio in Q2 2026, its #74 holding.
Baker Bros. Advisors first reported a position in LB Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
115 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q2 2026.

Based on Baker Bros. Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.